The main reasons why CD38 has become a tumor treatment target are as follows: (1) In a hypoxic TME, CD38 acts as an extracellular enzyme to catalyze NAD+ existing in the TME into ADPR or cADPR. The gene discussed is CD38; the disease is neoplasm.